|
1
|
Mareel M and Leroy A: Clinical, cellular,
and molecular aspects of cancer invasion. Physiol Rev. 83:337–376.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weigelt B, Peterse JL and Van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oldenburg RA, Meijers-Heijboer H,
Cornelisse CJ and Devilee P: Genetic susceptibility for breast
cancer: How many more genes to be found? Crit Rev Oncol Hematol.
63:125–149. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nowsheen S, Aziz K, Tran PT, Gorgoulis VG,
Yang ES and Georgakilas AG: Epigenetic inactivation of DNA repair
in breast cancer. Cancer Lett. 342:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
6
|
Yoo HS and Park TG: Biodegradable
polymeric micelles composed of doxorubicin conjugated PLGA-PEG
block copolymer. J Control Release. 70:63–70. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Low PS and Antony AC: Folate
receptor-targeted drugs for cancer and inflammatory diseases. Adv
Drug Deliv Rev. 56:1055–1058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu Y, Sega E, Leamon CP and Low PS: Folate
receptor-targeted immunotherapy of cancer: Mechanism and
therapeutic potential. Adv Drug Deliv Rev. 56:1161–1176. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hilgenbrink AR and Low PS: Folate
receptor-mediated drug targeting: From therapeutics to diagnostics.
J Pharm Sci. 94:2135–2146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Santra S, Kaittanis C, Santiesteban OJ and
Perez JM: Cell-specific, activatable, and theranostic prodrug for
dual-targeted cancer imaging and therapy. J Am Chem Soc.
133:16680–16688. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sledge GW, Neuberg D, Bernardo P, Ingle
JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of
doxorubicin, paclitaxel, and the combination of doxorubicin and
paclitaxel as front-line chemotherapy for metastatic breast cancer:
An intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heister E, Neves V, Silva SRP, Mcfadden J
and Coley HM: Carbon nanotubes loaded with anticancer drugs: A
platform for multimodal cancer treatmentCarbon Nanotubes for
Biomedical Applications. Klingeler R and Sim RB: Springer-Verlag
GmbH; Berlin: pp. 223–245. 2009
|
|
13
|
Karukstis KK, Thompson EH, Whiles JA and
Rosenfeld RJ: Deciphering the fluorescence signature of daunomycin
and doxorubicin. Biophys Chem. 73:249–263. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jakupec MA, Galanski M and Keppler BK:
Tumor-inhibiting platinum complexes-state of the art and future
perspectives. Rev Physiol Biochem Pharmacol. 146:1–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hall MD, Mellor HR, Callaghan R and
Hambley TW: Basis for design and development of platinum (IV)
anticancer complex. J Med Chem. 50:3403–3411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tyagi AK, Agarwal C, Chan DC and Agarwal
R: Synergistic anti-cancer effects of silibinin with conventional
cytotoxic agents doxorubicin, cisplatin and carboplatin against
human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep.
11:493–499. 2014.
|
|
17
|
Chun R, Kurzman ID, Couto CG, Klausner J,
Henry C and MacEwen EG: Cisplatin and doxorubicin combination
chemotherapy for the treatment of canine osteosarcoma: A pilot
study. J Vet Intern Med. 14:495–498. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harrington KJ, Syrigos KN, Uster PS,
Zetter A, Lewanski CR, Gullick WJ, Vile RG and Stewart JS: Targeted
radiosensitisation by pegylated liposome-encapsulated 3′,
5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer
xenograft model. Br J Cancer. 91:366–373. 2004.PubMed/NCBI
|
